JMP Securities Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $64.
January 11, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben reaffirmed a 'Market Outperform' rating on Mirum Pharmaceuticals, with a price target of $64.
The reiteration of a 'Market Outperform' rating by a reputable analyst typically signals continued confidence in the company's prospects, which can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100